IP Library Granted Patent US 8,951,794
Granted Patent B2
US 8,951,794 · App. 13/399,516 · Granted Feb 10, 2015

Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

Inventors: Nazeen Dewji (San Diego, CA); S. Jonathan Singer (La Jolla, CA)
Assignee: The Regents of the University of California
C07K14/4711A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,951,794
App. No.
13/399,516
Granted
Feb 10, 2015
Kind
B2
Abstract

The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.

Claims (33)

1. A method of inhibiting the production of Aβ comprising contacting mammalian cells expressing a β-amyloid precursor protein (β-APP) with an isolated polypeptide consisting essentially of an amino acid sequence from the N-terminal fragment of PS-1 (SEQ ID NO:2), wherein the fragment is selected from the group consisting of:

(i) DEEEDEEL (SEQ ID NO:5),

(ii) SEQ ID NO:5 further including 1-10 additional amino acids at either the N- and/or C-terminal end(s),

(iii) RRSLGHPEPLSNGRPQGNSRQWEQDEEEDEELTLKYGAK (SEQ ID NO:7),

(iv) a polypeptide that is 85% identical to SEQ ID NO:7 having 1-5 conservative amino acid substitutions,

(v) a sequence consisting of (iii) or (iv) further including 1-10 additional amino acids at the N- and/or C-terminal end(s),

(vi) DEEEDELTLKYGAK (SEQ ID NO:17),

(vii) SEQ ID NO:17 further including 1-5 conservative amino acid substitutions,

(viii) a sequence consisting of (vi) or (vii) further including 1-10 additional amino acids at the N- or C-terminus,

(ix) any of the foregoing polypeptides comprising an unnatural amino acid or D-amino acid, and

(x) combinations of any of the foregoing,

wherein the isolated polypeptide inhibits production of Aβ in a cell.

2. The method of claim 1 , wherein the isolated polypeptide consists of the amino acid sequence DEEEDEEL (SEQ ID NO:5).

3. The method of claim 1 , wherein the isolated polypeptide consists of the amino acid sequence SEQ ID NO:5 further including 1-10 additional amino acids at either the N- and/or C-terminal end(s).

4. The method of claim 1 , wherein the isolated polypeptide consists of the amino acid sequence RRSLGHPEPLSNGRPQGNSRQWEQDEEEDEELTLKYGAK (SEQ ID NO:7).

5. The method of claim 1 , wherein the isolated polypeptide is 85% identical to the amino acid sequence of SEQ ID NO:7 but has 1-5 conservative amino acid substitutions.

6. The method of claim 1 , wherein the isolated polypeptide consists of the amino acid sequence DEEEDEELTLKYGAK (SEQ ID NO:17).

7. A method of inhibiting interaction of β-amyloid precursor protein (β-APP) and presenilin-1 (PS-1) comprising contacting mammalian cells expressing β-APP and/or PS-1 with an isolated polypeptide consisting essentially of an amino acid sequence from the N-terminal fragment of PS-1 (SEQ ID NO:2), wherein the fragment is selected from the group consisting of:

(i) DEEEDEEL (SEQ ID NO:5),

(ii) SEQ ID NO:5 further including 1-10 additional amino acids at either the N- and/or C-terminal end(s),

(iii) RRSLGHPEPLSNGRPQGNSRQWEQDEEEDEELTLKYGAK (SEQ ID NO:7),

(iv) a polypeptide that is 85% identical to SEQ ID NO:7 having 1-5 conservative amino acid substitutions,

(v) a sequence consisting of (iii) or (iv) further including 1-10 additional amino acids at the N- and/or C-terminal end(s),

(vi) DEEEDELTLKYGAK (SEQ ID NO:17),

(vii) SEQ ID NO:17 further including 1-5 conservative amino acid substitutions,

(viii) a sequence consisting of (vi) or (vii) further including 1-10 additional amino acids at the N- or C-terminus,

(ix) any of the foregoing polypeptides comprising an unnatural amino acid or D-amino acid, and

(x) combinations of any of the foregoing,

wherein the isolated polypeptide inhibits interaction between β-APP and PS-1.

8. The method of claim 7 , wherein the isolated polypeptide consists of the amino acid sequence DEEEDEEL (SEQ ID NO:5).

9. The method of claim 7 , wherein the isolated polypeptide consists of the amino acid sequence RRSLGHPEPLSNGRPQGNSRQWEQDEEEDEELTLKYGAK (SEQ ID NO:7).

10. The method of claim 7 , wherein the polypeptide inhibits the production of Aβ.

11. The method of claim 7 , wherein the isolated polypeptide consists of the amino acid sequence DEEEDEELTLKYGAK (SEQ ID NO:17).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2014
From: DEWJI, NAZNEEN; SINGER, S. JONATHAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 034561/0584 →
CONFIRMATORY LICENSE Recorded Oct 16, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029134/0835 →
CONFIRMATORY LICENSE Recorded Jul 13, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028553/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2012
From: DEWJI, NAZNEEN; SINGER, S. JONATHAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 028228/0866 →
Continuity (5)
Continuation 12464850 · May 12, 2009
Continuation In Part 12264872 · Nov 4, 2008
Continuation In Part 11693926 · Mar 30, 2007
Provisional Application 60788524 · Mar 31, 2006
Related Publication 20120214235A1 · Aug 23, 2012